Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 6, 2020
Daily News
April 6, 2020
- Fujifilm Wako to Launch Coronavirus Test on April 15
April 6, 2020
- Sumitomo Dainippon, Ehime Univ. Aim to Make New Malaria Vaccine IND-Ready by March 2022
April 6, 2020
- Carcinogen in On-Market Nizatidine Products Acceptable Levels: MHLW
April 6, 2020
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
- Companies Should Reward Consistent Compliance with Detailing Guidelines in Performance Evaluations: MHLW Study
April 6, 2020
- Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
- Japan Mulling Free Avigan Supplies to 30-or-So Countries for COVID-19
April 6, 2020
- Japan Generic Market Crosses 1 Trillion Yen Mark in 2019: Fuji Keizai
April 6, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…